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The heterogeneous nature of the yellow fever (YF) 17D-204 vaccine virus population was exploited in this study to isolate
virus variants able to escape neutralization by the 17D-204 vaccine-specific MAb 864. The conformational change on the
virus surface that resulted in the loss of the MAb 864-defined epitope was effected in each variant by a single amino acid
mutation in the envelope (E) protein at either position E-305 or E-325. Interestingly, both positions were mutated during
attenuation of the 17D-204 vaccine substrain from the wildtype Asibi strain. The mutations in several of the variants
represented reversion to the wildtype Asibi virus sequence consistent with loss of a 17D-204 substrain-specific epitope. The
majority of the variant viruses were shown to have altered mouse neurovirulence phenotypes, ranging from complete
avirulence through to increased virulence. The avirulent variants are the first flavivirus MAb-neutralization-resistant variants
to be attenuated for neurovirulence in the adult mouse model. Overall, the results indicate that the E protein epitope
recognized by MAb 864 defines a functionally important region that encodes major molecular determinants of YF virus
pathogenesis in vivo. © 1998 Academic Press
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INTRODUCTION
Yellow fever (YF) virus is the prototype member of the
Flavivirus genus, family Flaviviridae. The flaviviruses are
small, enveloped viruses with a single-stranded, posi-
tive-sense RNA genome. The membrane-associated
membrane (M) and envelope (E) proteins constituting the
viral ‘‘spikes’’ perform many important functions, includ-
ing attachment of virus to specific host cell binding sites,
fusion of the viral envelope with host cell membranes,
virion assembly, and release. Accordingly, the conforma-
tion of the E protein may ultimately be expected to
influence viral pathogenicity in vivo.
Studies of the E protein’s role in the pathogenesis
process are facilitated by the selection of single-site
virus variants with altered ability to induce a fatal en-
cephalitis in the mouse model. Neutralizing monoclonal
antibodies (MAbs) can be used to select antigenic virus
variants in vitro, which are termed MAb neutralization-
resistant escape (MAbR) variants. This approach has
been used successfully to isolate MAbR variants for
several flaviviruses including tick-borne encephalitis
(TBE) (Mandl et al., 1989; Holzmann et al., 1990), Japa-
nese encephalitis (Cecilia and Gould, 1991; Hasegawa et
al., 1992), louping ill (Jiang et al., 1993), dengue-2 (Lin et
al., 1994), Murray Valley encephalitis (McMinn et al.,
1995), and YF (Lobigs et al., 1987; Ryman et al., 1997b)
viruses. Single amino acid mutations in the E protein
reducing the neuroinvasiveness of the virus following
peripheral inoculation of mice were observed in several
cases (Holzmann et al., 1990; Hasegawa et al., 1992;
Cecilia and Gould, 1991; McMinn et al., 1995). However,
to date no such MAbR variants with altered neuroviru-
lence when administered intracerebrally (ic) have been
characterized.
In this study, a series of MAbR variants was selected
for resistance to neutralization by MAb 864, previously
shown to be specific for a 17D-204 substrain vaccine
virus E protein epitope (Buckley and Gould, 1985; Gould
et al., 1985). MAb 864 is considered to define an impor-
tant functional site on the 17D-204 virus E protein, as
exemplified by its high reactivity in neutralization, hem-
agglutination inhibition (HAI), and passive protection
studies (Cammack and Gould, 1986). Moreover, the pres-
ence of the epitope recognized by MAb 864 exclusively
on 17D-204 vaccine viruses may be indirectly relevant to
the virulence of the YF vaccine viruses. Comparison of
the corresponding parent and MAb 864R variant viruses
revealed differential biological and antigenic profiles.
The molecular determinants of MAb neutralization es-
cape were identified by sequence analysis of the M and
E protein-encoding genes and the neurovirulence of the
864R variant viruses was examined in the mouse model.
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RESULTS AND DISCUSSION
Derivation and characterization of the 864R variant
viruses
Three series of MAbR variant viruses, derived from
17D-204-WHO, 17D(2wt) or 17D(1wt) virus, were iso-
lated by selection for neutralization resistance to the
17D-204 substrain-specific MAb 864 (Fig. 1). 17D-204-
WHO was selected to represent 17D-204 vaccine vi-
ruses, while the other two viruses were selected for their
unusual properties. The 17D(1wt) and 17D(2wt) variants
are plaque isolates from the 17D-204-UK vaccine virus
population, selected, respectively, for the presence or
absence of the E protein wildtype-specific epitope rec-
ognized by MAb 117 (Gould et al., 1989). The 17D(2wt)
variant is attenuated for mouse neurovirulence due to a
single mutation from 17D-204-UK at amino acid 240 in
the E protein (E-240). The 17D(1wt) variant has an addi-
tional mutation at E-173, resulting in presentation of the
MAb 117-defined wildtype-specific epitope and reversion
to neurovirulence in mice (Ryman et al., 1997a). In
PRNTs, 17D-204 substrain-specific MAb 864 neutralized
all three of these viruses greater than 104-fold. Seven
MAb 864 neutralization-resistant (864R) variant viruses
were plaque-purified and characterized; three from the
17D(1wt) virus, two from the 17D(2wt) virus and two
from the 17D-204-WHO vaccine virus. Loss of the MAb
864-defined epitope from the 864R variant viruses was
confirmed by indirect immunofluorescence (IIF). As ex-
pected, the wildtype-specific epitope recognized by MAb
117 was present on the 864R(1wt) variants, but absent
from the 864R (2wt) and 864R WHO variants. HAI assays
with a panel of MAbs revealed that, although their
epitopes remained physically present on the 864R vari-
ants (by IIF), they no longer had HAI activity, indicating a
subtle conformational change in the E protein.
Sequence analysis of the 864R variant viruses
Comparison of the M and E protein gene sequence of
the 864R variant viruses with their respective parent virus
revealed that, in each case, neutralization escape was
effected by a single amino acid mutation in the E protein
(Table 1). Substitutions of serine or valine for phenylalanine
at E-305 or leucine for serine at E-325 each resulted in loss
of the MAb 864-defined 17D-204 substrain-specific epitope,
mapping the 17D-204 substrain-specific epitope recog-
nized by MAb 864 in this region. It is interesting to note that
amino acid substitutions have occurred at both E-305 and
E-325 during the attenuation process of the wildtype strain
Asibi virus to generate the 17D vaccine viruses. A serine to
phenylalanine mutation at E-305 is conserved among the
17D vaccine strains, suggesting that this substitution may
also have existed in the original 17D attenuated variant
(Hahn et al., 1987; Jennings et al., 1993). Thus, the
864R(2wt)-2 variant reverted to the wildtype amino acid at
this position, while the 864R WHO-1 variant exhibited a third
variation. The 17D-204 substrain viruses also differed by a
proline to serine amino acid substitution at E-325 from Asibi
and 17DD substrain viruses. Therefore, 864R(2wt)-1, 864R
WHO-2, and the 864R(1wt) variants all had reverting muta-
tions at this position. These observations were consistent
with the 17D-204 substrain specificity of the MAb 864-
defined epitope.
The 864R(1wt) variant viruses were identical to the
17D(1wt) parental virus at amino acid position E-173,FIG. 1. Derivation of 864R variant viruses.
TABLE 1
Amino Acid Differences Identified between the 864R Viruses
and Their Respective Parent Viruses in the E Protein
E-153 E-173 E-240 E-305 E-325
Asibi N T A S P
17DD N I A F P
17D-204-UK N I A F S
17D(2wt) N I V F S
864R(2wt)1 N I V F L
864R(2wt)2 N I V S S
17D(1wt) N T V F S
864R(1wt)1 N T V F L
864R(1wt)2 N T V F L
864R(1wt)3 N T V F L
17D-204-WHO T I A F S
864RWHO-1 T I A V S
864RWHO-2 T I A F L
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consistent with the presence of the MAb 117-defined
wildtype-specific epitope. Consequently, the 864R(2wt)-1
variant virus differed from the 864R(1wt) variant viruses
only at position E-173; the difference observed between
the 17D(2wt) and 17D(1wt) parent viruses (Ryman et al.,
1997a). The 864R WHO variants lacked the E-240 substi-
tution, but had a substitution at E-153 that led to a
potential N-linked glycosylation site within the E protein
(Post et al., 1992).
Mouse neurovirulence of the 864R variants
The single amino acid mutations in the E protein ap-
peared to induce subtle conformational changes facilitating
MAb 864 neutralization escape and were found to have
profound effects on the virulence of the 864R variant viruses
in vivo. In adult mouse intracerebrally (ic) mortality studies
the 864R variants exhibited degrees of mouse neuroviru-
lence ranging from completely avirulent through rapidly
fatal (Table 2). In contrast to their 17D(1wt) parent virus
(85% mortality), the three 864R(1wt) variants were signifi-
cantly attenuated for mouse neurovirulence with mortality
rates ranging from 0 to 13%. Since these three viruses had
an identical mutation this is unlikely to be a significant
difference. Similarly, the 864R(2wt)-1 variant was attenu-
ated even further than its parent virus, 17D(2wt). In con-
trast, the 864R(2wt)-2 variant virus was found to be signif-
icantly more virulent than its parent 17D(2wt) virus, despite
being antigenically very similar to the completely avirulent
864R(2wt)-1 variant (data not shown). This represents the
reversion of an attenuated variant to the neurovirulent phe-
notype of the parental 17D-204-UK vaccine virus. Like the
17D-204-WHO vaccine virus, 864R WHO-2 was neuroviru-
lent, while 864R WHO-1 was significantly attenuated, killing
only 50% of infected mice. The surviving mice developed
clinical signs of infection, but subsequently recovered.
Mouse neuroinvasiveness of the 864R(2wt)-2 variant
virus
To further delineate the neurotropic properties of the
864R(2wt)-2 variant virus the neuroinvasiveness of this vi-
rus was tested by intraperitoneal (ip) inoculation of 8-day-
old mice. The 17D-204-UK vaccine virus, the 17D(2wt) par-
ent virus, and the 864R(2wt)-2 variant virus were avirulent
when administered by this route, whereas wildtype Asibi
virus was lethal (data not shown). Therefore, the
864R(2wt)-2 variant virus had not reverted to the wildtype
YF virus phenotype for neuroinvasiveness in suckling mice;
rather it had retained the attenuated phenotype of the 17D
vaccine viruses. Similarly, the 864R(2wt)-2 variant virus was
not virulent for mice following intranasal (i.n.) inoculation of
weanling mice (data not shown).
Replication of the 864R variant viruses in mouse brain
The ability of the 864R variants to replicate in mouse
brain following ic inoculation was directly correlated with
mortality (Table 3). Replication of the three 864R(1wt)
variants and the 864R(2wt)-1 variant in neuronal tissue
was clearly impeded as no infectious virus was detect-
able (,15 plaque-forming units (PFU)/brain) in the brains
of mice infected with these viruses at any time point
assayed. Virus titers in the brains of the 864R(2wt)-2
virus-infected mice were variable, but higher than the
17D(2wt) parent virus (Ryman et al., 1997a). Two days
postinfection (pi), infection had been established in two
of three mice with titers between 3 3 102 and 1 3 104
PFU/brain, increasing through 3 days pi Eight days pi,
virus titers had fallen below 7 3 103 PFU/brain and in
one mouse virus was no longer detectable, despite the
clinical signs of encephalitis displayed by all three mice
that were sampled. RT-PCR performed on a number of
these mouse brain homogenates demonstrated that the
presence of viral RNA correlated absolutely with infec-
tious virus titer, thus confirming the sensitivity of the
plaque assay (data not shown).
Histopathologic and immunohistochemical
examination of brain sections
Brain sections from one mouse inoculated with
864R(2wt)-1 and one inoculated with 864R(2wt)-2, har-
vested 8 days pi, were examined. Routine hematoxin and
eosin staining revealed very little pathology of the brain
in either case (data not shown). Some focal meningeal,
perivascular, and parenchymal inflammation was ob-
served in brain sections from both mice. Additionally,
possible ventricular inflammation and microglial nodules
were found in the mouse infected with the 864R(2wt)-2
variant virus. There was no evidence of demyelination
and immunocytochemical staining was unable to detect
TABLE 2
Neurovirulence of the 864R Variant Viruses Compared with Their
Parent Viruses 17D(2wt), 17D(1wt), and 17D-204-WHO
Virus
No. dead/
No. inoculated
%
Mortality
Average survival time
(AST) in days
(6SEM)
17D-204-UK 10/10 100% 10.3 6 0.6
17D(2wt) 8/45 17.7% 9.5 6 0.5
864R(2wt)-1 0/26 ,4% NA
864R(2wt)-2 9/9 100% 9.2 6 1.1
17D(1wt) 17/20 85% 10.1 6 0.5
864R(1wt)-1 0/8 ,12.5% NA
864R(1wt)-2 1/9 11% NA
864R(1wt)-3 1/8 12.5% NA
17D-204-WHO 8/8 100% 11.0 6 0.7
864RWHO-1 4/8 50% 9.5 6 1.0
864RWHO-2 8/8 100% 9.6 6 0.5
Note. Adult mice were inoculated ic with 104 PFU of virus. N.A., not
applicable.
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any viral antigen in either brain. In comparison, limited
viral antigen was detectable in sections of a control
mouse brain infected with 17D-204-UK virus.
Genetic correlates of pathogenesis
864R(2wt)-1 and the 864R(1wt) variants with com-
bined mutations at E-240 and E-325 no longer induced
lethal encephalitis in mice following ic inoculation and
were highly attenuated with respect to their parent vi-
ruses and 17D-204-UK. This attenuation apparently re-
sulted from the reduced ability of these viruses to repli-
cate in mouse brain. However, in the background of the
17D-204-WHO vaccine strain the same E-325 amino acid
substitution did not attenuate the virulence of the 864R
WHO-2 variant. This suggests either that the E-153 mu-
tation negates the effects of the E-325 mutation,or that
the E-240 change in the 17D(1wt) and 17D(2wt) variants
is essential to the attenuated phenotype.
Reversion of the E-305 amino acid in variant
864R(2wt)-2 to the serine observed in the Asibi wildtype
virus led to the reemergence of the neurovirulent pheno-
type. In this instance the substituted amino acid led to
more efficient replication of the virus in neuronal tissue.
This mutation is able to reverse the effects of the E-240
mutation which attenuated the 17D(2wt) variant virus
(Ryman et al., 1997a) relative to 17D-204-UK vaccine
virus. In contrast, the 864R WHO-1 variant, with a unique
valine substitution at E-305, was significantly attenuated
for mouse neurovirulence. Overall, it appears that amino
acid substitutions at E-240 and E-325 have a cooperative
effect and that the molecular basis of mouse neuroviru-
lence is multifactorial. These findings emphasize the
critical role of the E protein in the mechanism of viral
pathogenesis.
Interpretation of amino acid substitutions in the 3D
structure of the E protein
Rey et al. (1995) have recently determined the three-
dimensional structure of the ectodomain of the TBE virus
E protein. Due to the conservation of the disulfide
bridges among flaviviruses, the TBE virus E protein
model can be used to approximate the structure of the
YF virus E protein. This model is shown in Fig. 2, viewed
from above (Fig. 2A) and from the side (Fig. 2B), with the
sites of amino acid substitutions reported in this paper
highlighted. Although fairly distant on the linear protein
sequence, on the predicted E protein structure and as
demonstrated by the antibody footprint in Fig. 2A, the
substitutions at E-305 and E-325 are closely oriented,
consistent with the proposal that MAb 864 binds to a
conformation-dependent epitope (Despre´s et al., 1990).
These amino acids map to domain III of the E protein,
which has previously been implicated in the tissue tro-
pism of flaviviruses (see Rey et al., 1995, for an overview).
It is proposed, therefore, that the altered neurovirulence
phenotypes displayed by the 864R variant viruses are a
direct consequence of changes in the E protein affecting
tissue tropism. Indeed, the presence of amino acid sub-
stitutions at E-305 in all 17D vaccine viruses and E-325 in
the 17D-204 substrain suggests that changes in this
region may have contributed to the attenuation of these
viruses. In addition, the model predicts that E-173 and
TABLE 3
Infectivity Titres in Infected Mouse Brain Homogenate
Virus
Day
postinoculation
Infectivity titre
(PFU/brain)
17D(2wt) 15
2 3.0 3 102
3.0 3 102
1.0 3 104
3 ,15
,15
1.6 3 103
8 ,15
,15
864R(2wt)-1 ,15
2 ,15
,15
,15
3 ,15
,15
,15
8 ,15
,15
864R(2wt)-2 15
2 1.0 3 104
3.0 3 102
4.5 3 104
3 3.0 3 103
3.6 3 105
,15
8 7.0 3 103
3.4 3 102
17D(1wt) 1.5 3 103
2 2.4 3 104
9.0 3 103
7.5 3 103
3 4.5 3 103
2.0 3 104
3.6 3 105
8 2.0 3 106
5.3 3 105
,15
864R(1wt)-1 11 ,15
,15
,15
864R(1wt)-2 11 ,15
,15
,15
864R(1wt)-2 11 ,15
,15
Note. RT-PCR results represent detection (1) or not (2) of 1331-bp
amplicon from the E protein gene.
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E-240 are spatially distinct regions of the E protein from
E-305 and E-325 (Fig. 2). Therefore, it is proposed that
amino acid substitutions at E-173 and E-240 alter the
conformation of the protein, thereby altering the viru-
lence phenotype of the virus.
It is possible to speculate on the mechanism of altered
neurovirulence. In radioimmunoprecipitation and West-
ern blotting analyses, MAb 864 recognizes the E and prM
proteins (Gould et al., 1985, 1989). This suggests that the
17D-204 substrain-specific epitope is directly or indi-
rectly associated with the prM–E interaction and that
mutation in this epitope alters the prM–E interaction.
This proposal is supported by Guirakhoo et al. (1992),
who have found that prM interacts with the E protein
between E-200 and E-327 for MVE virus.
Conclusions
Although virus virulence is likely to be multigenic, this
study presents the first indication that the pathogenesis
of YF virus in vivo can be directly linked to specific
epitopes on the surface of the E protein. As mentioned
previously, the 17D-204 substrain-specific epitope recog-
nized by MAb 864 is involved in a number of biological
activities: neutralization (Buckley and Gould, 1985), HAI
(Gould et al., 1986), hemolysis (Cammack and Gould,
1985), and passive protection (Gould et al., 1986). This
study has revealed that loss of the MAb 864-defined
epitope may result in the expression of a significantly
altered mouse neurovirulence phenotype. Clearly, there-
fore, this epitope is also important in determining the
neurovirulence of YF virus in mice and, as suggested by
Cammack and Gould (1985), is a critical epitope on the E
protein of YF virus.
MATERIALS AND METHODS
Virus strains and cell culture
YF vaccine viruses 17D-204-UK (Wellcome Biotechnol-
ogy, UK; Batch No. YF/1/274) and 17D-204-WHO (World
Health Organization; avian leukosis virus-free secondary
seed) were obtained as freeze-dried doses of commer-
cial vaccine. Two plaque-purified strains of 17D-204-UK,
one with and one without the wildtype specific epitope
recognized by MAb 117, termed 17D(1wt) and 17D(2wt),
respectively (Gould et al., 1989; Ryman et al., 1997a),
were kindly provided by Dr. E. A. Gould. Viruses were
passed once through monkey kidney Vero cells to pro-
vide working stocks and for extraction of viral RNA for
molecular analysis. Virus was titered by plaque assay in
Vero cells and expressed as PFU/ml.
FIG. 2. Diagrammatic representation of the folded structure of the ectodomain of the E polypeptide in the dimer. (A) The dimer viewed looking down
on the virus particle; (B) the dimer viewed from the side of the virus particle. Highlighted residues (E-153, E-173, E-240, E-305, and E-325) are variable
amino acids in the YF virus E protein (see Table 1). The shaded box in (A) represents the approximate size of an antibody footprint.
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Monoclonal antibodies, indirect immunofluorescence,
and hemagglutination inhibition
YF wildtype-specific MAb 117 and 17D-204 vaccine
substrain-specific MAb 864 were provided by Dr. E. A.
Gould and were used as dilutions of MAb-containing
mouse ascitic fluid (Gould et al., 1985, 1989). IIF tests and
HAI assays were performed as described previously
(Barrett et al., 1989).
Selection of MAbR variant viruses
Potential MAbR variant viruses, which appeared as
plaques resistant to neutralization by MAb 864, were
plaque-purified according to the method of Wiktor and
Koprowski (1980) and passed once on Vero cell mono-
layers to provide working stocks. The loss of the MAb
864-defined E protein epitope from these candidate 864R
variants was confirmed by IIF and PRNTs.
Nucleotide sequence analysis
Viral genomic RNA was extracted from infected Vero
cell culture supernatant as described by Ni et al. (1995).
For each 864R variant virus the region of the genome
encoding the M and E proteins was amplified by RT-PCR
in two overlapping fragments as described by Lewis et
al. (1990) and modified by Jennings et al. (1993). Gel-
purified cDNA fragments were cloned and sequenced in
duplicate.
Animal experiments
Groups of 3- to 4-week-old, female, outbred strain T0
(Harlan Olac, UK) or NIH Swiss (Harlan, CA) mice were
inoculated ic or i.n. with 104 PFU virus in a 20-ml volume.
Litters of 8-day-old, outbred NIH Swiss mice (Harlan, CA)
were inoculated by the ip route with 104 PFU virus in 20
ml. The morbidity and/or mortality of infected mice were
monitored daily for up to 37 days. Average survival time
and percentage mortality were calculated where appli-
cable. In parallel experiments, 3- to 4-week-old mice
were sacrificed by cervical spinal dislocation at various
time points pi. Mouse brain tissue was processed for
virus titration or histopathological examination as de-
scribed in Ryman et al. (1997a).
Histopathology and immunohistochemistry
Formalin-fixed whole mouse brains were sliced into
five blocks of uniform thickness and location using stan-
dard landmarks on the base of the brain, except where
an inoculation site was evident, in which case the slicing
was modified to include that site in one section. Section-
ing and staining were performed as described by Cao et
al. (1995).
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